Skip to content

EBIT at other companies

XER
Xeris Biopharma Holdings, Inc.XERS
$7.92M+356%
Innoviva, Inc. logo
Innoviva, Inc.INVA
$38.15M-7.9%
Zevra Therapeutics, Inc. logo
Zevra Therapeutics, Inc.ZVRA
$52.15M+1,073%
ANI Pharmaceuticals logo
ANI PharmaceuticalsANIP
$38.89M+48.5%
Theravance Biopharma logo
Theravance BiopharmaTBPH
-$9.48M+34.3%
Eton Pharmaceuticals, Inc. logo
Eton Pharmaceuticals, Inc.ETON
$2.41M+614%

Other financials

Income statement

See full
Revenue-
Operating income-$39.0M-37.1%
Net income-$37.3M-40.0%
EPS (diluted)-$0.15-25.0%

Balance sheet

See full
Cash & equivalents$38.8M+98.4%
Total debt$30.1M+1.8%
Total equity$176.0M+19.1%
Total assets$221.6M+17.1%

Cash flow

See full
Operating cash flow-$33.0M-21.5%
CapEx$54.0K+1,700%
Free cash flow-$33.1M-21.7%

Valuation

See full
Market cap$1.19B+247%
Enterprise value$1.19B+235%
P/S4,648.7×

Profitability

See full
Operating margin-19,183.3%
Net margin-19,305.1%
FCF margin-15,518.7%

Returns & leverage

See full
Return on equity-80%+4.7pp
Debt / equity0.2×0.0×
Current ratio13.5×-1.4×

Where this comes from

Calculated from Savara’s reported figures.

Plus components not separately reported this period.

The official record: Savara’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about Savara's ebit.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Savara's EBIT?
Savara (SVRA) reported EBIT of -$38.99M in Q1 2026.
How has Savara's EBIT changed year-over-year?
Savara's EBIT decreased by 37.1% year-over-year, from -$28.44M to -$38.99M.
What is the long-term trend for Savara's EBIT?
Over 4 years (2021 to 2025), Savara's EBIT has grown at a 31.4% compound annual growth rate (CAGR), from -$41.48M to -$123.55M.
What does EBIT mean?
Earnings before interest and taxes — the profit from the business before financing cost and tax. Uses reported operating income where a company reports it; otherwise pre-tax income plus interest expense. Lets companies be compared on earning power independent of capital structure.